Abstract
Genetic variants associated with Alzheimer's disease (AD) through genome-wide association studies (GWAS) are challenging to interpret because most lie in non-coding regions of the genome. Here, a method was developed that integrates deep learning variant effect prediction (DL-VEP) scores from Enformer, DeepSea, and ChromBPNet models with cell-type specific regulatory annotations to improve fine-mapping of causal AD variants. Using stratified linkage disequilibrium score regression, the largest proportion of heritability among brain cell types was found in microglia and the integration of Enformer microglia-based transcription factor DL-VEP scores and microglia ChromBPNet models further localizes the AD polygenic signal allowing for improved fine-mapping of causal AD variants. Functionally-informed fine-mapping using these annotations discovers 101 AD risk variants compared to 87 identified by statistical fine-mapping alone. Importantly, polygenic risk scores derived from these fine-mapped variants show improved cross-ancestry performance in both African American (AUC=0.532 vs. 0.521 for SUSIE) and Hispanic (AUC=0.552 vs. 0.535 for SUSIE) populations, while maintaining strong performance in European populations (AUC=0.620 vs. 0.615 for SUSIE). Through detailed analysis of the PICALM/EED locus, we demonstrate how our approach disentangles causal variants in regions of high linkage disequilibrium and predicts specific molecular mechanisms, such as disruption of PU.1 transcription factor binding, with the posterior inclusion probability of this variant increasing from 0.55 using SUSIE to 0.90 with our method. Our results provide a framework for leveraging deep learning annotations to improve identification of causal disease variants and enhance polygenic risk prediction across diverse populations.
Competing Interest Statement
T.R. served as a scientific advisor for Merck and serves as a consultant for Curie.Bio
Funding Statement
Research reported in this paper was supported by the Alzheimer's Disease Sequencing Project of the National Institutes of Health under award number U01 AG068880-02. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of the New York Genome Center gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
This paper uses the Alzheimer's Disease Sequence Project Release 5 Whole Genome Sequencing data and Alzheimer's Disease phenotype data. Summary statistics for Alzheimer's disease GWAS are publicly available through the GWAS catalog. Ascension ID: GCST007511, GCST90044699, GCST90027158.
https://www.ebi.ac.uk/gwas/studies/GCST007511